Free Trial

Mana Capital Acquisition (MAAQ) Competitors

$4.58 +0.17 (+3.85%)
As of 07/24/2025

MAAQ vs. MOLN, JMAC, THTX, LIMN, NKTX, CGEN, LXEO, LYEL, TNYA, and JATT

Should you be buying Mana Capital Acquisition stock or one of its competitors? The main competitors of Mana Capital Acquisition include Molecular Partners (MOLN), Maxpro Capital Acquisition (JMAC), Theratechnologies (THTX), Liminatus Pharma (LIMN), Nkarta (NKTX), Compugen (CGEN), Lexeo Therapeutics (LXEO), Lyell Immunopharma (LYEL), Tenaya Therapeutics (TNYA), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry.

Mana Capital Acquisition vs. Its Competitors

Mana Capital Acquisition (NASDAQ:MAAQ) and Molecular Partners (NASDAQ:MOLN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, Molecular Partners had 2 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 2 mentions for Molecular Partners and 0 mentions for Mana Capital Acquisition. Molecular Partners' average media sentiment score of 0.94 beat Mana Capital Acquisition's score of 0.00 indicating that Molecular Partners is being referred to more favorably in the news media.

Company Overall Sentiment
Mana Capital Acquisition Neutral
Molecular Partners Positive

Mana Capital Acquisition has higher earnings, but lower revenue than Molecular Partners.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mana Capital AcquisitionN/AN/AN/AN/AN/A
Molecular Partners$5.65M28.65-$61.39M-$1.92-2.09

Mana Capital Acquisition's return on equity of 0.00% beat Molecular Partners' return on equity.

Company Net Margins Return on Equity Return on Assets
Mana Capital AcquisitionN/A N/A N/A
Molecular Partners N/A -42.20%-38.12%

68.4% of Mana Capital Acquisition shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Molecular Partners has a consensus price target of $12.00, suggesting a potential upside of 199.33%. Given Molecular Partners' stronger consensus rating and higher possible upside, analysts plainly believe Molecular Partners is more favorable than Mana Capital Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mana Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Molecular Partners
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

Summary

Molecular Partners beats Mana Capital Acquisition on 8 of the 11 factors compared between the two stocks.

Get Mana Capital Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for MAAQ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MAAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MAAQ vs. The Competition

MetricMana Capital AcquisitionIn Vitro, In Vivo Diagnostic Substances IndustryManufacturing SectorNASDAQ Exchange
Market Cap$37.21M$37.21M$2.27B$9.50B
Dividend YieldN/AN/A2.57%4.01%
P/E RatioN/AN/A22.0720.05
Price / SalesN/AN/A82.5789.38
Price / CashN/AN/A29.1858.56
Price / BookN/AN/A55.705.87
Net IncomeN/AN/A-$121.61M$258.55M
7 Day Performance6.51%6.51%0.97%3.73%
1 Month Performance30.86%30.86%2.13%11.75%
1 Year Performance882.83%882.83%25.21%18.03%

Mana Capital Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MAAQ
Mana Capital Acquisition
N/A$4.58
+3.9%
N/A+847.8%$37.21MN/A0.001Gap Up
MOLN
Molecular Partners
2.5584 of 5 stars
$3.63
-0.7%
$12.00
+231.0%
-31.5%$147.37M$5.65M-1.89180News Coverage
JMAC
Maxpro Capital Acquisition
N/A$6.45
+7.3%
N/A+2,900.0%$145.16MN/A0.002,021Gap Up
THTX
Theratechnologies
N/A$3.14
-0.3%
N/A+119.4%$144.61M$85.87M-16.53140Positive News
LIMN
Liminatus Pharma
N/A$5.42
-0.9%
N/AN/A$142.30MN/A0.00N/ANews Coverage
Gap Down
NKTX
Nkarta
1.768 of 5 stars
$1.91
-4.5%
$14.33
+650.4%
-68.7%$141.91MN/A-1.26140Positive News
CGEN
Compugen
1.4458 of 5 stars
$1.54
-3.1%
$4.00
+159.7%
-13.1%$141.89M$27.86M-9.6370
LXEO
Lexeo Therapeutics
2.0379 of 5 stars
$4.15
-2.6%
$16.60
+300.0%
-65.0%$141.42M$650K-1.2658
LYEL
Lyell Immunopharma
2.5105 of 5 stars
$9.24
-2.9%
$15.00
+62.3%
-61.9%$140.97M$60K-0.37270News Coverage
Gap Up
TNYA
Tenaya Therapeutics
3.9387 of 5 stars
$0.88
+1.3%
$6.25
+612.6%
-79.1%$140.89MN/A-0.76110Positive News
JATT
JATT Acquisition
N/A$1.96
+51.9%
N/A-54.6%$140.76MN/A0.003High Trading Volume

Related Companies and Tools


This page (NASDAQ:MAAQ) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners